MedPath

Cindome Pharma, Inc

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:1
Completed:1

Trial Phases

1 Phases

Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)โ€ข Click on a phase to view related trials

Phase 2
4 (100.0%)

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

Phase 2
Recruiting
Conditions
Idiopathic Gastroparesis
Interventions
Drug: CIN-102 Dose 15mg
Drug: CIN-102 Dose 10mg
Drug: Placebo
First Posted Date
2025-03-27
Last Posted Date
2025-07-20
Lead Sponsor
CinDome Pharma, Inc.
Target Recruit Count
400
Registration Number
NCT06899217
Locations
๐Ÿ‡บ๐Ÿ‡ธ

G & L Research, LLC, Foley, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

The Center for Clinical Trials, Saraland, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Del Sol Research Management, LLC, Tucson, Arizona, United States

and more 69 locations

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Phase 2
Active, not recruiting
Conditions
Diabetic Gastroparesis
Interventions
Drug: CIN-102 Dose 15mg or 10mg
Drug: Placebo
First Posted Date
2023-04-27
Last Posted Date
2025-08-22
Lead Sponsor
CinDome Pharma, Inc.
Target Recruit Count
382
Registration Number
NCT05832151
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Digestive Health Specialists of the Southeast, Dothan, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

G & L Research, LLC, Foley, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Clinical Research Associates, LLC, Huntsville, Alabama, United States

and more 96 locations

A Scintigraphy Study in Adults With Diabetic Gastroparesis

Phase 2
Terminated
Conditions
Diabetic Gastroparesis
Interventions
Drug: Placebo for CIN-102
Drug: CIN-102 Dose 1
Drug: CIN-102 Dose 2
First Posted Date
2019-12-23
Last Posted Date
2021-08-10
Lead Sponsor
CinDome Pharma, Inc.
Target Recruit Count
2
Registration Number
NCT04208698
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site, El Paso, Texas, United States

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Phase 2
Completed
Conditions
Gastroparesis
Interventions
Drug: CIN-102 Dose 1
Drug: Placebo
Drug: CIN-102 Dose 2
Drug: CIN-102 Dose 3
First Posted Date
2019-07-19
Last Posted Date
2021-07-21
Lead Sponsor
CinDome Pharma, Inc.
Target Recruit Count
73
Registration Number
NCT04026997
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site 101, Chula Vista, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Research Site 114, Jacksonville, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Research Site 117, Miami, Florida, United States

and more 16 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.